Search Results

You are looking at 1 - 10 of 11 items for :

  • "blood-based biomarker" x
  • Refine by Access: All content x
Clear All
Free access

Veronica R Placencio-Hickok, Anisha Madhav, Sungjin Kim, Frank Duong, Bryan Angara, Zhenqiu Liu, and Neil A Bhowmick

While the overall 5-year survival rate for prostate cancer is near 100%, up to 35% of patients will develop recurrent disease. At the time of prostatectomy, prostate-specific antigen (PSA) is used to guide primary therapy with the goal of curative intervention. It can be valuable to know when primary therapy may not in fact be curative, so that subsequent adjuvant therapy can be administered at an early stage to limit progression. We examined prostate cancer patients with PSA ≤10 ng/mL that were all subjected to prostatectomy with at least 5 years of follow-up (n = 181). Based on data that endoglin (CD105) signaling in the tumor can contribute to prostate cancer progression, we examined the expression of soluble CD105 (sCD105) in the patient plasma. To determine the relation of plasma sCD105 measures to cellular CD105 in tissues, we tested an independent set of prostate cancer tissues and paired plasma (n = 31). Elevated sCD105 was found to be associated with recurrence-free survival of prostate cancer patients. Further, sCD105 levels in patient plasma were inversely correlated with cellular CD105 expression. This translational study supported preclinical data demonstrating the pro-tumorigenic capacity of cellular CD105 and provide a blood-based biomarker, sCD105, for prostate cancer recurrence in prostatectomy patients with PSA levels ≤10 ng/mL.

Free access

Maria Chiara Zatelli, Erika Maria Grossrubatscher, Elia Guadagno, Concetta Sciammarella, Antongiulio Faggiano, and Annamaria Colao

et al . 2016 ) or phosphorylated histone H3 assessment ( Villani et al . 2016 ). Besides tissue-based characteristics, blood-based biomarkers have been considered, also due to easy accessibility of the compartment and possibility of multiple sampling

Free access

C R C Pieterman, S M Sadowski, J E Maxwell, M H G Katz, K E Lines, C M Heaphy, A Tirosh, J E Blau, N D Perrier, M A Lewis, J P Metzcar, D M Halperin, R V Thakker, and G D Valk

-up of nf-PanNETs in patients with MEN1 Question 1: Do we need new blood-based biomarkers for the diagnosis of nf-PanNETs in MEN1 and how should we study this? State of evidence Current clinical practice guidelines, published in 2012, balanced

Free access

Benjamin C Thomas, Jonathan D Kay, Suraj Menon, Sarah L Vowler, Sarah N Dawson, Laura J Bucklow, Hayley J Luxton, Thomas Johnston, Charlie E Massie, Michelle Pugh, Anne Y Warren, Peter Barker, Keith Burling, Andy G Lynch, Anne George, Johanna Burge, Marie Corcoran, Sara Stearn, Alastair D Lamb, Naomi L Sharma, Greg L Shaw, David E Neal, and Hayley C Whitaker

H Wang Y Ruderman DL Agus DB Mallick P Gross ME 2013 Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype . Prostate 73 306 – 315 . ( doi:10

Free access

Xiao-hui Luo, Jian-zhou Liu, Bo Wang, Qun-li Men, Yu-quan Ju, Feng-yan Yin, Chao Zheng, and Wei Li

.1530/JME-16-0005 Bacos K Gillberg L Volkov P Olsson AH Hansen T Pedersen O Gjesing AP Eiberg H Tuomi T Almgren P , et al . 2016 Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes

Free access

Maria Chiara Zatelli, Giuseppe Fanciulli, Pasqualino Malandrino, Valeria Ramundo, Antongiulio Faggiano, Annamaria Colao, and on behalf of NIKE Group

most likely to respond. The role of blood-based biomarkers has been recently addressed in a consensus review, which underlined the important limitations of monoanalyte biomarkers and the potential importance of circulating multianalyte biomarkers in

Restricted access

Mojun Zhu, Karl R Sorenson, Rebecca Liu, Bonnie E Gould Rothberg, and Thorvardur R Halfdanarson

-off points. Other peripheral blood-based biomarkers such as NLR face similar challenges as testing methods, and cut-off points tend to differ by institution. In the class of cellular markers, the expression of HSP90 ( Gamboa et al. 2020 ), α

Open access

Frédéric R Santer, Kamilla Malinowska, Zoran Culig, and Ilaria T Cavarretta

Walz J Roehrborn CG Montorsi F Margulis V Saad F Slawin KM Karakiewicz PI 2008 Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers

Free access

S Prekovic, T Van den Broeck, S Linder, M E van Royen, A B Houtsmuller, F Handle, S Joniau, W Zwart, and F Claessens

17 18 – 22 . ( https://doi.org/10.1038/pcan.2013.56 ) 10.1038/pcan.2013.56 24366413 Kani K Malihi PD Jiang Y Wang H Wang Y Ruderman DL Agus DB Mallick P Gross ME 2013 Anterior gradient 2 (AGR2): blood‐based biomarker elevated in metastatic

Free access

Jennifer L Bishop, Alastair Davies, Kirsi Ketola, and Amina Zoubeidi

2013 Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype . Prostate 73 306 – 315 . ( doi:10.1002/pros.22569 ). Karhadkar SS Bova GS Abdallah N Dhara S